New T‑cell therapy targets three tumor proteins, shows early survival gains in aggressive pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National Hospital using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors.

These findings, published in Nature Medicine, are particularly significant given the challenges of treating pediatric brain tumors, which remain the leading cause of cancer-related deaths in children.

Immunotherapies have been shown to work in blood cancers but rarely succeed in solid tumors, especially brain tumors. ...